奥西默替尼
医学
T790米
肿瘤科
内科学
肺癌
队列
化疗
表皮生长因子受体
埃罗替尼
癌症
吉非替尼
作者
Masayuki Takeda,Mototsugu Shimokawa,Atsushi Nakamura,Kaname Nosaki,Yasutaka Watanabe,Terufumi Kato,Daisuke Hayakawa,Hiroshi Tanaka,Toshiaki Takahashi,Yoshihito Kogure,Motoko Tachihara,Daichi Fujimoto,Kakuhiro Yamaguchi,Naohiko Hamaguchi,Isamu Okamoto,Koichi Azuma,Kazuo Hasegawa,Nobuyuki Yamamoto,Kazuhiko Nakagawa
标识
DOI:10.1016/j.cllc.2020.12.009
摘要
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has recently been established as a standard treatment option for chemotherapy-naive patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). However, only about one-half of patients who have received prior treatment with a first- or second-generation EGFR-TKI are eligible for osimertinib therapy because its indication in the second-line setting is limited to metastatic NSCLC positive for the T790M resistance mutation of EGFR. The dose-escalation part of a study in which patients received osimertinib at doses of 20 to 240 mg once daily after the development of resistance to first- or second-generation EGFR-TKIs revealed a response rate of 21% and a median progression-free survival of 2.8 months for individuals whose tumors were negative for EGFR T790M. We have now designed a phase II study of osimertinib for patients with EGFR mutation-positive NSCLC who develop isolated central nervous system progression (T790M-negative or unknown) after first- or second-generation EGFR-TKI therapy (cohort 1) or who develop systemic disease progression (T790M-negative) after first- or second-generation EGFR-TKI therapy and platinum-based chemotherapy (cohort 2). A total of 70 patients (cohort 1, n = 17; cohort 2, n = 53) will be enrolled in this study, which originated from a suggestion of a dedicated network for patients with lung cancer in Japan.
科研通智能强力驱动
Strongly Powered by AbleSci AI